Targeting the mitochondrial permeability transition: Cardiac ischemia-reperfusion versus carcinogenesis

Cellular Physiology and Biochemistry

Volumn 27, Issue 3-4, 2011, Pages 179-190

  Javadov, Sabzali ^a   Hunter, J Craig ^b   Barreto Torres, Giselle ^a   Parodi Rullan, Rebecca ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Cancer; Cardiac ischemia reperfusion; Cardioprotection; Chemotherapy; Mitochondrial permeability transition

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ATRACTYLOSIDE; BETA PHENYLETHYL ISOTHIOCYANATE; BETULIC ACID; BONGKREKIC ACID; CARIPORIDE; CLODRONIC ACID; CYCLOSPORIN A; GADOLINIUM TEXAPHYRIN; IMEXON; LEVO BUTHIONINE SULPHOXAMINE; LONIDAMINE; MANGAFODIPIR; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NORPHENAZONE; PROPOFOL; SANGLIFEHRIN A; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL SWELLING; COLON CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DYSPLASTIC NEVUS; GLIOBLASTOMA; GLIOMA; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LUNG CANCER; MELANOMA; MITOCHONDRIAL PERMEABILITY; NECROSIS; NEUROBLASTOMA; OUTER MEMBRANE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; SOLID TUMOR;

EID: 79953803842     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000327943     Document Type: Review

References (127)

1. Chipuk JE, Bouchier-Hayes L, Green DR: Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 2006;13:1396-1402. (Pubitemid 44057475)
2. Lucken-Ardjomande S, Montessuit S, Martinou JC: Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ 2008;15:929-937. (Pubitemid 351524434)
3. Halestrap AP, Pasdois P: The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009;1787:1402-1415.
4. Javadov S, Karmazyn M, Escobales N: Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 2009;330:670-678.
5. Baines CP: The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 2009;46:850-857.
6. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M: Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005;38:367-374. (Pubitemid 40215206)
7. Hausenloy DJ, Yellon DM: The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-341. (Pubitemid 36411694)
8. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP: Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-524. (Pubitemid 36701762)
9. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM: Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 2005;289:H237-242.
10. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M: Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
11. Fantin VR, Leder P: Mitochondriotoxic compounds for cancer therapy. Oncogene 2006;25:4787-4797. (Pubitemid 44187626)
12. Brenner C, Grimm S: The permeability transition pore complex in cancer cell death. Oncogene 2006;25:4744-4756. (Pubitemid 44192088)
13. Fulda S, Galluzzi L, Kroemer G: Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-464.
14. Armstrong JS: Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007;151:1154-1165.
15. Hunter DR, Haworth RA, Southard JH: Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem 1976;251:5069-5077.
16. Petronilli V, Szabo I, Zoratti M: The inner mitochondrial membrane contains ion-conducting channels similar to those found in bacteria. FEBS Lett 1989;259:137-143. (Pubitemid 20009965)
17. Szabo I, Zoratti M: The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem 1991;266:3376-3379. (Pubitemid 21909221)
18. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blachly-Dyson E, Di Lisa F, Forte MA: The mitochondrial permeability transition from in vitro artifact to disease target. Febs J 2006;273:2077-2099.
19. Robertson CL, Scafidi S, McKenna MC, Fiskum G: Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury. Exp Neurol 2009;218:371-380.
20. Krauskopf A, Eriksson O, Craigen WJ, Forte MA, Bernardi P: Properties of the permeability transition in VDAC1(-/-) mitochondria. Biochim Biophys Acta 2006;1757:590-595. (Pubitemid 43993836)
21. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD: Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 2007;9:550-555. (Pubitemid 46696536)
22. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC: The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004;427:461-465. (Pubitemid 38168501)
23. Leung AW, Varanyuwatana P, Halestrap AP: The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem 2008;283:26312-26323.
24. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P: Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005;280:18558-18561. (Pubitemid 41379552)
25. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD: Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434:658-662. (Pubitemid 40488559)
26. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y: Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434:652-658. (Pubitemid 40488558)
27. Min L, Fulton DB, Andreotti AH: A case study of proline isomerization in cell signaling. Front Biosci 2005;10:385-397. (Pubitemid 40543041)
28. Bernardi P, Vassanelli S, Veronese P, Colonna R, Szabo I, Zoratti M: Modulation of the mitochondrial permeability transition pore. Effect of protons and divalent cations. J Biol Chem 1992;267:2934-2939.
29. Adhihetty PJ, Ljubicic V, Menzies KJ, Hood DA: Differential susceptibility of subsarcolemmal and intermyofibrillar mitochondria to apoptotic stimuli. Am J Physiol Cell Physiol 2005;289:C994-C1001. (Pubitemid 41361653)
30. Bera AK, Ghosh S, Das S: Mitochondrial VDAC can be phosphorylated by cyclic AMP-dependent protein kinase. Biochem Biophys Res Commun 1995;209:213-217.
31. Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping P: Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 2003;92:873-880. (Pubitemid 36542528)
32. Javadov S, Rajapurohitam V, Kilic A, Zeidan A, Choi A, Karmazyn M: Antihypertrophic effect of NHE-1 inhibition involves GSK-3beta-dependent attenuation of mitochondrial dysfunction. J Mol Cell Cardiol 2009;46:998-1007.
33. Griffiths EJ, Halestrap AP: Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
34. Kerr PM, Suleiman MS, Halestrap AP: Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am J Physiol 1999;276:H496-502.
35. Javadov S, Choi A, Rajapurohitam V, Zeidan A, Basnakian AG, Karmazyn M: NHE-1 inhibition-induced cardioprotection against ischaemia/reperfusion is associated with attenuation of the mitochondrial permeability transition. Cardiovasc Res 2008;77:416-424. (Pubitemid 351197641)
36. Prendes MG, Torresin E, Gonzalez M, Fernandez MA, Perazzo JC, Savino EA, Varela A: Protection of ischaemic-reperfused rat heart by dimethylamiloride is associated with inhibition of mitochondrial permeability transition. Clin Exp Pharmacol Physiol 2008;35:201-206.
37. Linz WJ, Busch AE: NHE-1 inhibition: from protection during acute ischaemia/reperfusion to prevention/reversal of myocardial remodelling. Naunyn Schmiedebergs Arch Pharmacol 2003;368:239-246. (Pubitemid 37372546)
38. Karmazyn M, Sostaric JV, Gan XT: The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure. Drugs 2001;61:375-389. (Pubitemid 32270046)
39. 2+ - and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007;117:2431-2444.
40. Oliveira PJ, Seica R, Coxito PM, Rolo AP, Palmeira CM, Santos MS, Moreno AJ: Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 2003;554:511-514. (Pubitemid 37412541)
41. Javadov S, Huang C, Kirshenbaum L, Karmazyn M: NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J Mol Cell Cardiol 2005;38:135-143. (Pubitemid 40038660)
42. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN: Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 2007;42:150-158. (Pubitemid 44958623)
43. Fang J, Seki T, Maeda H: Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009;61:290-302.
44. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110. (Pubitemid 38736063)
45. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, Coon A, Dorr RT: Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther 2002;1:185-195.
46. Biaglow JE, Miller RA: The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005;4:6-13. (Pubitemid 41350919)
47. Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S, Galeotti T: Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem 2004;11:1299-1308. (Pubitemid 38585068)
48. Tonissen KF, Di Trapani G: Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009;53:87-103.
49. Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S: Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood 2002;99:655-663. (Pubitemid 34533105)
50. Papp B, Brouland JP, Gelebart P, Kovacs T, Chomienne C: Endoplasmic reticulum calcium transport ATPase expression during differentiation of colon cancer and leukaemia cells. Biochem Biophys Res Commun 2004;322:1223-1236. (Pubitemid 39164652)
51. Shinohara Y, Ishida T, Hino M, Yamazaki N, Baba Y, Terada H: Characterization of porin isoforms expressed in tumor cells. Eur J Biochem 2000;267:6067-6073.
52. Halestrap AP, Brennerb C: The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem 2003;10:1507-1525. (Pubitemid 36896553)
53. Dolce V, Scarcia P, Iacopetta D, Palmieri F: A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. FEBS Lett 2005;579:633-637.
54. Bauer MK, Schubert A, Rocks O, Grimm S: Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J Cell Biol 1999;147:1493-1502.
55. Zamora M, Granell M, Mampel T, Vinas O: Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett 2004;563:155-160. (Pubitemid 38471591)
56. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E, Brenner C: Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 2006;66:9143-9152. (Pubitemid 44521134)
57. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G: Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-2031. (Pubitemid 28475490)
58. Belzacq AS, Vieira HL, Verrier F, Vandecasteele G, Cohen I, Prevost MC, Larquet E, Pariselli F, Petit PX, Kahn A, Rizzuto R, Brenner C, Kroemer G: Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res 2003;63:541-546. (Pubitemid 36152519)
59. Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y, Stepien G: ANT2 isoform required for cancer cell glycolysis. J Bioenerg Biomembr 2005;37:307-316. (Pubitemid 41778770)
60. Faure Vigny H, Heddi A, Giraud S, Chautard D, Stepien G: Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol Carcinog 1996;16:165-172. (Pubitemid 26299420)
61. Bonod-Bidaud C, Chevrollier A, Bourasseau I, Lachaux A, Mousson de Camaret B, Stepien G: Induction of ANT2 gene expression in liver of patients with mitochondrial DNA depletion. Mitochondrion 2001;1:217-224. (Pubitemid 33586030)
62. Li Y, Johnson N, Capano M, Edwards M, Crompton M: Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J 2004;383:101-109. (Pubitemid 39389455)
63. Schubert A, Grimm S: Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. Cancer Res 2004;64:85-93. (Pubitemid 38114085)
64. Machida K, Ohta Y, Osada H: Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J Biol Chem 2006;281:14314-14320. (Pubitemid 43848360)
65. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H: Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol 2000;60:397-402. (Pubitemid 30336637)
66. Maaser K, Hopfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M, Scherubl H: Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 2001;85:1771-1780. (Pubitemid 34081526)
67. Okaro AC, Fennell DA, Corbo M, Davidson BR, Cotter FE: Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Gut 2002;51:556-561.
68. Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, Poupon MF: Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 2002;62: 1388-1393. (Pubitemid 34407797)
69. Pratt R, Vallis LM, Lim CW, Chisnall WN: Mitochondrial creatine kinase in cancer patients. Pathology 1987;19:162-165. (Pubitemid 17094218)
70. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M: The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999;5:1758-1766. (Pubitemid 29334457)
71. Manion MK, Hockenbery DM: Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2003;2:S105-114.
72. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M: Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000;97:10872-10877.
73. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-969. (Pubitemid 27087710)
74. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL: Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 1996;56:2468-2471. (Pubitemid 26170674)
75. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH: Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002;1555:14-20. (Pubitemid 35245999)
76. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V: In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004;377:347-355.
77. Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
78. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V: Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol Chem 2009;284:3946-3955.
79. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-6673. (Pubitemid 32896483)
80. Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA: Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 2002;99:12825-12830.
81. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
82. Halestrap AP, Davidson AM: Inhibition of Ca2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 1990;268:153-160. (Pubitemid 20166664)
83. Regula KM, Ens K, Kirshenbaum LA: Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002;91:226-231. (Pubitemid 34875677)
84. Akao M, O'Rourke B, Teshima Y, Seharaseyon J, Marban E: Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. Circ Res 2003;92:186-194. (Pubitemid 36254274)
85. Haworth RA, Hunter DR: Control of the mitochondrial permeability transition pore by high-affinity ADP binding at the ADP/ATP translocase in permeabilized mitochondria. J Bioenerg Biomembr 2000;32:91-96. (Pubitemid 30241261)
86. Xu M, Wang Y, Hirai K, Ayub A, Ashraf M: Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis. Am J Physiol Heart Circ Physiol 2001;280:H899-908.
87. Wang G, Liem DA, Vondriska TM, Honda HM, Korge P, Pantaleon DM, Qiao X, Wang Y, Weiss JN, Ping P: Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 2005;288:H1290-1295.
88. de Macedo DV, Nepomuceno ME, Pereira-da-Silva L: Involvement of the ADP/ATP carrier in permeabilization processes of the inner mitochondrial membrane. Eur J Biochem 1993;215:595-600.
89. Clarke SJ, McStay GP, Halestrap AP: Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 2002;277:34793-34799.
90. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ: Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 2005;102:12005-12010. (Pubitemid 41291119)
91. Zhou S, Heller LJ, Wallace KB: Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001;175:60-67. (Pubitemid 32783536)
92. + exchanger isoform 1 inhibition is mediated by reduced mitogen-activated protein kinase activation secondary to improved mitochondrial integrity and decreased generation of mitochondrial-derived reactive oxygen species. J Pharmacol Exp Ther 2006;317:1036-1043.
93. 2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2006;290:H2024-2034.
94. Javadov SA, Lim KH, Kerr PM, Suleiman MS, Angelini GD, Halestrap AP: Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res 2000;45:360-369. (Pubitemid 30069501)
95. Rajesh KG, Sasaguri S, Suzuki R, Maeda H: Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol 2003;285:H2171-2178.
96. Takeda T, Akao M, Matsumoto-Ida M, Kato M, Takenaka H, Kihara Y, Kume T, Akaike A, Kita T: Serofendic acid, a novel substance extracted from fetal calf serum, protects against oxidative stress in neonatal rat cardiac myocytes. J Am Coll Cardiol 2006;47:1882-1890.
97. de Jesus Garcia-Rivas G, Guerrero-Hernandez A, Guerrero-Serna G, Rodriguez-Zavala JS, Zazueta C: Inhibition of the mitochondrial calcium uniporter by the oxo-bridged dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in postischemic rat heart. FEBS J 2005;272:3477-3488. (Pubitemid 40979316)
98. + exchange inhibitor, inhibits the mitochondrial death pathway. Circulation 2003;108:2275-2281.
99. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
100. Fulda S, Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-4811. (Pubitemid 44187627)
101. Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99-163. (Pubitemid 46209992)
102. Majima E, Ikawa K, Takeda M, Hashimoto M, Shinohara Y, Terada H: Translocation of loops regulates transport activity of mitochondrial ADP/ATP carrier deduced from formation of a specific intermolecular disulfide bridge catalyzed by copper-o-phenanthroline. J Biol Chem 1995;270:29548-29554.
103. McStay GP, Clarke SJ, Halestrap AP: Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J 2002;367:541-548. (Pubitemid 35216831)
104. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G: Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000;19:307-314. (Pubitemid 30077228)
105. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ: A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3:497-509. (Pubitemid 38340296)
106. Kroemer G, de The H: Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-745.
107. Costantini P, Chernyak BV, Petronilli V, Bernardi P: Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 1996;271:6746-6751. (Pubitemid 26104106)
108. Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-1262 (Pubitemid 34441791)
109. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM: Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998;273:33942-33948. (Pubitemid 29008858)
110. Eiznhamer DA, Xu ZQ: Betulinic acid: a promising anticancer candidate. IDrugs 2004;7:359-373.
111. Slack JL, Rusiniak ME: Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000;79:227-238. (Pubitemid 30307449)
112. Hsu CA, Rishi AK, Su-Li X, Gerald TM, Dawson MI, Schiffer C, Reichert U, Shroot B, Poirer GC, Fontana JA: Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997;89:4470-4479. (Pubitemid 27260257)
113. Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin SA, Kroemer G, Formstecher P: The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999;59:6257-6266.
114. Notario B, Zamora M, Vinas O, Mampel T: All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol Pharmacol 2003;63:224-231. (Pubitemid 36043826)
115. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, Kroemer G: Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001;20:7579-7587. (Pubitemid 33111858)
116. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G: Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999;18:2537-2546.
117. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-4646. (Pubitemid 44187614)
118. Han X, Yoon SH, Ding Y, Choi TG, Choi WJ, Kim YH, Kim YJ, Huh YB, Ha J, Kim SS: Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep 2010;23:1053-1062.
119. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA: An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA 2007;104:11832-11837. (Pubitemid 47175098)
120. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R: Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 2007;25:1779-1784. (Pubitemid 46797961)
121. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A: Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004;11:737-746. (Pubitemid 39023120)
122. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-252. (Pubitemid 44311067)
123. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B, Singh SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010;285:26558-26569.
124. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, Batteux F: Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006;98:236-244. (Pubitemid 43264707)
125. Magda D, Miller RA: Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 2006;16:466-476. (Pubitemid 44780135)
126. Palmeira CM, Wallace KB: Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol Appl Pharmacol 1997;143:338-347. (Pubitemid 27183551)
127. Wallace KB: Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007;7:101-107.